Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Prostate Cancer

Treatments: Drug: Comparator: placebo (unspecified); Drug: rofecoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00060476

2006_414

0966-201

MK0966-201

Formally-P30A03LD

Details and patient eligibility

About

To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.

Full description

The duration of treatment is 6 years.

Enrollment: 15,000 patients

Sex: Male

Ages: 50 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Regular PSA testing and study biopsies required.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind